The global metastatic castration-sensitive prostate cancer treatment market is experiencing significant growth. This increase can be attributed to factors such as an growing older population, rising prevalence of prostate cancer, and developments in treatment choices. The market is moreover driven by enhanced knowledge about the disease and its tre